Many studies have already demonstrated that pulsing of DCs with MHC-I restricted tumor-derived peptides or whole tumor cell lysates leads to induction of CD8+ T cell-mediated anti-cancer responses in vitro and in vivo [7]. The gene discussed is CD8A; the disease is neoplasm.